Company profile

Regenosca SA

Regenosca’s patented technology TissueSpan results in off-the-shelf and ready to use implants to avoid a second surgical site in soft tissue repair surgeries. They are engineered to be a noninvasive alternative to patient’s own tissue grafts that are currently used in clinics. Proof-of-concept is validated in an ongoing First-in-Man study where implants were successfully used to repair urethral strictures. The gold standard treatment is the use of patient’s own inner mouth tissue. Avoiding tissue harvesting means less pain, lower risks of complications, and shorter surgery times. TissueSpan implants will render soft tissue repair less invasive and fill the gap of missing biomaterials.

More news about Regenosca SA

19.07.2023 16:50

Swiss Medtechs seek growth opportunities in Boston

Please login or
register to use the
awards follow feature
01.04.2021 13:27

Les meilleures startups suisses de Bilan révélées

Please login or
register to use the
awards follow feature
27.11.2020 14:31

Regenosca wins CHF 150,000 to support bladder reconstruction

Please login or
register to use the
awards follow feature
12.11.2020 15:54

Medtech and Cleantech startups get boosted

Please login or
register to use the
awards follow feature
25.06.2020 14:46

Membrasenz ravit le Trophée PERL 2020

Please login or
register to use the
awards follow feature
Regenosca SA

Founded
2019

Kanton
VD


LinkedIn

Homepage

rss